文献速递运动医学

硬化蛋白抗体治疗促进动物模型肩袖腱骨愈合

Sclerostin Antibody Treatment Enhances Rotator Cuff Tendon-to-Bone Healing in an Animal Model.
PubMed 文献 · J Bone Joint Surg Am · 2017-01-01

本研究在动物模型中于肩袖修复时皮下给予硬化蛋白抗体(Scl-Ab)并每2周一次至处死,评估2、4、8周愈合。8周时Scl-Ab组骨密度较对照高30%,强度高38%、刚度高43%,组织学见腱骨整合更好,骨内成骨相关基因表达增强,肌腱基因表达无影响。

要点

  • 动物肩袖修复模型中,Scl-Ab每2周皮下给药至处死,8周时骨密度较对照高30%。
  • 8周时Scl-Ab组生物力学强度较对照高38%、刚度高43%。
  • 组织学显示Scl-Ab在8周时促进腱骨整合,骨内成骨基因表达增强,肌腱基因表达无影响。

核心结论

  • 本研究提供证据表明Scl-Ab治疗通过增加附着点骨密度改善肩袖腱骨愈合,从而改善生物力学性能。

研究设计与样本

  • 动物模型研究,于肩袖修复时皮下给予Scl-Ab并每2周一次直至处死,在愈合2、4、8周进行骨形态计量、生物力学、组织学和基因表达评估。

主要发现

  • 对照与Scl-Ab组在愈合2周和4周时损伤修复导致骨密度降低。
  • 愈合8周时Scl-Ab组骨密度较对照高30%。
  • 愈合4周时两组生物力学性能均较健康腱骨附着降低。
  • 愈合8周时Scl-Ab组强度较对照高38%、刚度高43%。
  • 组织学评估显示Scl-Ab在8周时促进腱骨更好整合,骨内基因表达显著增强提示成骨增强,肌腱基因表达无影响。

临床怎么用

  • 作者指出Scl-Ab治疗可能改善肩袖修复后的结局。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rotator cuff tears are a common source of pain and disability, and poor healing after repair leads to high retear rates. Bone loss in the humeral head before and after repair has been associated with poor healing. The purpose of the current study was to mitigate bone loss near the repaired cuff and improve healing outcomes. METHODS: Sclerostin antibody (Scl-Ab) treatment, previously shown to increase bone formation and strength in the setting of osteoporosis, was used in the current study to address bone loss and enhance rotator cuff healing in an animal model. Scl-Ab was administered subcutaneously at the time of rotator cuff repair and every 2 weeks until the animals were sacrificed. The effect of Scl-Ab treatment was evaluated after 2, 4, and 8 weeks of healing, using bone morphometric analysis, biomechanical evaluation, histological analysis, and gene expression outcomes. RESULTS: Injury and repair led to a reduction in bone mineral density after 2 and 4 weeks of healing in the control and Scl-Ab treatment groups. After 8 weeks of healing, animals receiving Scl-Ab treatment had 30% greater bone mineral density than the controls. A decrease in biomechanical properties was observed in both groups after 4 weeks of healing compared with healthy tendon-to-bone attachments. After 8 weeks of healing, Scl-Ab-treated animals had improved strength (38%) and stiffness (43%) compared with control animals. Histological assessment showed that Scl-Ab promoted better integration of tendon and bone by 8 weeks of healing. Scl-Ab had significant effects on gene expression in bone, indicative of enhanced bone formation, and no effect on the expression of genes in tendon. CONCLUSIONS: This study provides evidence that Scl-Ab treatment improves tendon-to-bone healing at the rotator cuff by increasing attachment-site bone mineral density, leading to improved biomechanical properties. CLINICAL RELEVANCE: Scl-Ab treatment may improve outcomes after rotator cuff repair.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Shah SA, Kormpakis I, Havlioglu N, et al. Sclerostin Antibody Treatment Enhances Rotator Cuff Tendon-to-Bone Healing in an Animal Model. J Bone Joint Surg Am. 2017. PMID: 28509826. doi:10.2106/JBJS.16.01019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。